VALANX Biotech, a MedTech startup now based in Vienna, has completed a financing round of 3 million euros. The company plans to use the capital to advance its main program for developing an antibody-drug conjugate (ADC) for metastatic triple-negative breast cancer. Candidate selection for VLX-ADC-001 is planned for June 2026. As reported, the company, formerly based in Klosterneuburg, last received a capital injection of 2.3 million euros in 2023 ( more on this here ). New and existing